Are you struggling to increase clinical trial awareness, recruitment, and participant retention for your oncology drug trials? Building up an efficient pre-screening process becomes an urgent task for companies to connect with potential participants; keep them engaged through the trial…
Privo Technologies, Inc. ("Privo"), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be "Tough on cancer, Easy on patients", announced today a poster presentation on the safety and efficacy of PRV111 in patients with early-stage Head and Neck Squamous Cell…
Closes $5 million Series A financing Appoints Pritesh J. Gandhi, PharmD, as Chief Executive Officer and Annie Partisano, PharmD, MS, as Senior Vice President and Head of Operations Announces exclusive license of TellDx platform to Genetron Holdings Limited for China…
Today is International Women’s Day. In honor of the occassion, the AIM-HI Accelerator Fund (AIM-HI) would like to highlight for you our venture philanthropy effort to provide critically needed seed funding to an underserved population: women scientist-entrepreneurs devoted to address…
Privo Technologies to Receive $900,000 of Investment Funding Privo Technologies and its chief executive officer, Manijeh Goldberg, Ph.D., have been selected as the winner of the AIM-HI Accelerator Fund’s inaugural Women’s Venture Competition, a first of its kind program for…
On Childhood Cancer Day, SHEPHERD Therapeutics is joining forces with Oncoheroes Biosciences to bring new treatment options to children and adolescents with cancer. SHEPHERD is a Boston-based biotech company on a mission to change the way rare cancer is treated,…
Every year, people around the world connect on a special day to support and remember the families and individuals affected by cancer. This day is called World Cancer Day, on February 4th. Over the past two decades, World Cancer Day…
An additional venture philanthropy organization, the Catalytic Impact Foundation, which supports women’s health, brain health, children’s health, aging, and pediatric rare disease initiatives, is investing in AIM-HI Accelerator Fund portfolio company Oncoheroes Biosciences, further validating the start-up’s unique effort to…
The AIM-HI Accelerator Fund is proud to support our Portfolio Company, SciTech Development, to present at the Virtual 2021 China BioMed Forum during the 39th J.P. Morgan Healthcare Conference. This Virtual Event will take place on January 11-12, 2021, co-hosted…
The AIM-HI Accelerator Fund sincerely thanks Microsoft for being a generous sponsor and supporting our inaugural Women’s Venture Competition program to provide various opportunities to women-led oncology start-ups! Only 2% of all venture money go to women-led early stage companies.…
